Anti-TNF (tumor necrosis factor) therapeutics are top-grossing drugs that are a major treatment advancement for inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and Crohn’s disease. Patient blood levels of TNF blockers need routine monitoring to ensure effective therapeutic response and patient safety. The current clinical test for TNF blockers is expensive and time-consuming, requiring cell culturing.

University of Utah researchers have developed an immunoassay platform with customized antibody detection reagents that enables one-step anti-TNF drug monitoring. The immunoassay provides a fluorimetric readout in less than an hour.